Siva Koganti
Overview
Explore the profile of Siva Koganti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Estrada C, Cardona S, Guo Y, Revelo M, DAgati V, Koganti S, et al.
Kidney Int
. 2022 Apr;
102(1):58-77.
PMID: 35483525
Thrombotic microangiopathy (TMA) in the kidney represents the most severe manifestation of kidney microvascular endothelial injury. Despite the source of the inciting event, the diverse clinical forms of kidney TMA...
2.
Sonkar C, Varshney N, Koganti S, Jha H
Mol Biol Rep
. 2022 Jan;
49(3):2519-2530.
PMID: 35031925
Introduction: Many pathogens have coexisted with humans for millennia and can cause chronic inflammation which is the cause of gastritis. Gastric cancer (GC) is associated with 8.8% of cancer related...
3.
McIntosh M, Koganti S, Boatwright J, Li X, Spadaro S, Brantly A, et al.
PLoS Pathog
. 2020 Oct;
16(10):e1008849.
PMID: 33002095
Epstein-Barr virus (EBV) causes lymphomas and epithelial cell cancers. Though generally silent in B lymphocytes, this widely prevalent virus can cause endemic Burkitt lymphoma and post-transplant lymphoproliferative disorders/lymphomas in immunocompromised...
4.
Rajkumar K, Mvs S, Koganti S, Burgula S
Int J Nanomedicine
. 2020 Jul;
15:4523-4540.
PMID: 32606692
Purpose: Selenium nanoparticles (SeNP) have several applications in the field of biotechnology, including their use as anti-cancer drugs. The purpose of the present study is to analyze the efficacy of...
5.
Koganti S, Burgula S, Bhaduri-McIntosh S
Virology
. 2020 Jan;
540:160-164.
PMID: 31928997
The cancer-causing Epstein-Barr virus (EBV) activates the transcription factor STAT3 upon infecting B-lymphocytes. STAT3 then activates caspase 7 to degrade cellular claspin, resulting in impaired Chk1 phosphorylation. This blockade of...
6.
Li X, Burton E, Koganti S, Zhi J, Doyle F, Tenenbaum S, et al.
J Virol
. 2018 Apr;
92(14).
PMID: 29695433
Cancer-causing herpesviruses infect nearly every human and persist indefinitely in B lymphocytes in a quiescent state known as latency. A hallmark of this quiescence or latency is the presence of...
7.
Lapsia S, Koganti S, Spadaro S, Rajapakse R, Chawla A, Bhaduri-McIntosh S
J Med Virol
. 2015 Aug;
88(2):312-8.
PMID: 26307954
Anti-TNFα therapy, known to suppress T-cell immunity, is increasingly gaining popularity for treatment of autoimmune diseases including inflammatory bowel diseases (IBD). T-cell suppression increases the risk of B-cell EBV-lymphoproliferative diseases...
8.
Koganti S, Clark C, Zhi J, Li X, Chen E, Chakrabortty S, et al.
J Virol
. 2015 Feb;
89(9):5002-11.
PMID: 25717101
Unlabelled: A major hurdle to killing Epstein-Barr virus (EBV)-infected tumor cells using oncolytic therapy is the presence of a substantial fraction of EBV-infected cells that does not support the lytic...
9.
Koganti S, Hui-Yuen J, McAllister S, Gardner B, Grasser F, Palendira U, et al.
Proc Natl Acad Sci U S A
. 2014 Mar;
111(13):4946-51.
PMID: 24639502
DNA damage response (DDR) is a signaling network that senses DNA damage and activates response pathways to coordinate cell-cycle progression and DNA repair. Thus, DDR is critical for maintenance of...
10.
Hui-Yuen J, Koganti S, Bhaduri-McIntosh S
Methods Mol Biol
. 2014 Feb;
1131:183-9.
PMID: 24515466
Infection of primary B lymphocytes with Epstein-Barr virus gives rise to growth-transformed and immortalized lymphoblastoid cell lines (LCL) in vitro. Among their many applications is the use of LCL to...